Moving From Heart Failure Guidelines to Clinical Practice: Gaps Contributing to Readmissions in Patients With Multiple Comorbidities and Older Age

Pupalan Iyngkaran¹, Danny Liew², Christopher Neil³, Andrea Driscoll⁴,⁵, Thomas H Marwick⁶ and David L Hare⁷,⁸

¹Northern Territory Medical Program, Flinders University, Darwin, NT, Australia. ²School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia. ³Department of Medicine—Western Precinct, The University of Melbourne, Melbourne, VIC, Australia. ⁴School of Nursing and Midwifery, Deakin University, Geelong, VIC, Australia. ⁵Austin Health, Melbourne, VIC, Australia. ⁶Baker Heart and Diabetes Institute, Melbourne, VIC, Australia. ⁷Cardiovascular Research, The University of Melbourne, Melbourne, VIC, Australia. ⁸Heart Failure Services, Austin Health, Melbourne, VIC, Australia.

ABSTRACT: This feature article for the thematic series on congestive heart failure (CHF) readmissions aims to outline important gaps in guidelines for patients with multiple comorbidities and the elderly. Congestive heart failure diagnosis manifests as a 3-phase journey between the hospital and community, during acute, chronic stable, and end-of-life (palliative) phases. This journey requires variable intensities a combination of multidisciplinary care within tertiary hospital or ambulatory care from hospital outpatients or primary health services, within the general community. Management goals are uniform, ie, to achieve the lowest New York Heart Association class possible, with improvement in ejection fraction, by delivering gold standard therapies within a CHF program. Comorbidities are an important common denominator that influences outcomes. Comorbidities include diabetes mellitus, chronic obstructive airways disease, chronic renal impairment, hypertension, obesity, sleep apnea, and advancing age. Geriatric care includes the latter as well as syndromes such as frailty, falls, incontinence, and confusion. Many systems still fail to comprehensively achieve all aspects of such programs. This review explores these factors.

KEYWORDS: elderly, geriatric, comorbidity, readmissions, translating guidelines, translational research

Introduction

Improvement in ejection fraction (RF) and congestive heart failure (CHF) class is the primary goal of management, and are associated with better prognosis. Doing so will also reduce readmissions.¹,² In the United States, prevalence of CHF is >5.7 million, with 670,000 new cases yearly. In Europe and globally, prevalence is >15 million and 37.7 million, respectively.³ Congestive heart failure hospitalization rates are high, and it is the leading cause in patients >65 years of age, with more than 1 million primary presentations or 1% to 2% of all hospitalizations yearly. Annual Medicare expenditure in the United States exceeds US $17 billion.⁴–⁶ Following a CHF admission, 1 in 4 are readmitted within the first month and half within 6 months, where 80% of emergency room presentations are admitted.⁷–¹³ Matching funding to readmission strategies such as pay for performance or fee-for-service, which are either health system or client focused, has not generated the desired outcomes within traditional models of care.¹¹ In addition, presentations, readmissions, and costs for CHF are projected to increase by 50% by 2035.¹⁴–¹⁷

To achieve New York Heart Association (NYHA) functional class 1 with an improved EF, the early focus of pharmacologic therapies is now interwoven into a complex program with a range of services and therapies requiring multidisciplinary input. The OPTIMIZE-HF study showed that when such programs are used to deliver care, outcomes could be improved.¹⁸ Studies also tell us that the gap between obtaining the highest class of evidence (Class 1A), the grade of recommendation, and the need to continually fine-tune evidence at the community level remains an understudied area. Thus, the future must in some fashion envision broader clarification in recommendations taking into account an aging population with multiple comorbidities.¹⁹,²⁰ Could this be an important consideration when addressing readmissions?

More than half of CHF patients will suffer a concomitant comorbidity such as diabetes, chronic renal impairment (CRI), smoking-induced lung diseases, obesity, sleep apnea, hypertension, and atrial fibrillation (AF).²¹ The elderly are also challenged by having greater comorbidities, psychological, and social vulnerability as well as geriatric syndromes such as falls, confusion, and frailty.²²–²⁴ It is not yet clear whether merely translating guidelines from a homogeneous randomized clinical trial to heterogeneous population translates to improved outcomes and reduced hospital admissions. In this review, we...
explore CHF guidelines in the context of comorbid disease and advancing age focusing on opportunities to close the guideline gaps.

Understanding Registry and Trial Data in Translating Guidelines
Congestive heart failure still carries a grave prognosis at all-time intervals, 30 days, 1, 5, and 10 years. These differences can be greater across racial subgroups and global health systems. The etiology of CHF and associated risk factors also contributes to this. Although age-adjusted incidence, prevalence, and mortality are decreasing, the absolute number of patients are increasing as patients live longer. Postdischarge event rates remain high, whereas length of hospital stay is shorter for an increasingly complex patient cohort. Congestive heart failure is thus an epidemic, where rates are projected to increase, and uses resources on many fronts the most costly being hospitalizations. Table 1 summarizes the publications that have covered this in greater detail.

Natural history of heart failure and the burden on health system
Progression of CHF or left ventricular (LV) recovery for any individual varies with the factors that influence the degree of ventricular remodeling and the causes. The greatest responders are seen with abnormalities in energetics, followed by toxins, and inflammatory cardiomyopathies. Readmissions are high when the remodeling process negatively affects systolic function. All cases will follow a 3-phase terrain of lifetime readmission risk with the highest risk “transition phase” and “palliative phase” and lowest in “plateau phase” (Figure 1). The cost of HF care accumulates largely from repeated hospitalization, because ambulatory care for complex CHF, with comorbidities and for elderly patients are yet to find the most cost-efficient model.

What have we learned from registries?
Most CHF cases are diagnosed in hospital and all patients will be admitted at some point. The past several decades have produced large, high-quality, multicenter registries, some with interventions that provided epidemiologic data as well as insight into the process of care (Table 1). The American Heart Association (AHA) has also published benchmarks for CHF taxonomy and clinical performance standards.

Registries based on benchmarked data paired with interventions that optimize the delivery of proven strategies, alone, can deliver improvement in all performance measures such as readmissions and outcomes, largely through improved adherence to guidelines. Intervention tools include: evidence-based practice algorithms, standardized order sets, and discharge checklist; and access to specialist, with only 52% of Medicare patients receiving inpatient review when readmitted. Rewards-based system such as fee-for-service or award centers appear less significant. Gaps in authoritative data matching sociodemographics, comorbidities and older age support need for more heterogenous studies. Risk scoring tools are yet to deliver meaningful roles in clinical assessments.

Heart Failure and Comorbidities
Early calls for recognizing multiple comorbidities are increasingly factored in both American and European CHF management guidelines. Positions are also increasingly provided. There remain large gaps due to homogeneity of randomized clinical trials. Among Medicare beneficiaries, 68% have ≥2 and 14% have ≥6 chronic conditions, among beneficiaries with CHF specifically >40% to 55% have ≥5 noncardiac comorbidities, which increase preventable and all hospitalizations proportionally. These points have consequences for management and guidelines. We focus on diabetes mellitus (DM), CRI, chronic obstructive pulmonary disease (COPD), sleep-disordered breathing (SDB), and obesity, where guidelines are yet to recommend (advocate) a specific as opposed to generic advice.

Significance of comorbidities, trial evidence, and impacts on readmissions
First, the Global Burden of Disease Study listed 17 primary causes, with two-thirds secondary to ischemic, hypertensive, rheumatic heart diseases, and COPD. Other causes include valvular, primary genetic/hereditary and acquired, secondary (systemic diseases) cardiomyopathies, congenital heart disease, and pericardial diseases. Causes are variably associated with greater comorbidities and association with socioeconomic status and developed nation status.

Second, among 4,366,489 Medicare beneficiaries with CHF, the top ranked comorbidities are hypertension (85.6%), ischemic heart disease (72.1%), hyperlipidemia (62.6%), anemia (51.2%), DM (47.1%), arthritis (45.6%), CRI (44.8%), chronic airways disease (30.9%), and AF (28.8%). Many noncardiac conditions are excluded during the run in period of randomized controlled trials (RCTs).

Third, in the clinical domain, a wider racial demography, female sex, and older population are managed, whereas data remain limited or or in some cases unreliable due to variations in case definition, sampling strategies, and enrollment. Observational evidence does support greater incidence in developing nations with greater comorbidities and disease burden, and socioeconomic disadvantage in some racial groups, eg, African Americans or even variations in disease patterns e.g women and East Asians.

It is thus no surprise that patient and homogenous system delivery factors are both equally risk factors for readmission. How resources are allocated within the 8 categories and 34...
Table 1. Summary of findings from key heart failure hospitalization registries.

| CHARACTERISTICS REPORTED | KEY FINDINGS |
|--------------------------|-------------|
| **Epidemiology**         |             |
| ● Incidence: Global 100-900/100,000; Framingham (1950-1999): F ↓ M (~420-327 vs 564 cases/100,000 pyr). Olmstead Country (2000-2010) M and F ↓ 43% and 29%. Greater in African Americans and developing nations. |
| ● Prevalence: 1% to 2% developed nations. Global 37.7 million; range <1% 40 years old; 2% ↑ each decade, peak 10% >80 years old. Lifetime risk 40 to 80 years old is 40%. |
| ● Prognosis: Framingham M 62% and F 42% 5y; over each decade ↓ by 10% to 11%. In 1990-1999, 33% improvement. Current 5-y mortality 50%; median survival 4.2 y (developing nations 2.61-3.72); >65 years old 30d and 12mo 27.5%; Inpatient mortality declining 38%, 16.4% for 30d and 12mo. |
| ● Admissions: 1979-2004: ↑ primary CHF diagnosis 219 to 390/100,000 pyr, and 3x ↑ admissions27,28 |
| ● Olmstead County: 1.34 admissions ppy, 63% noncardiac29 |
| ● 1999 and 2011 (Medicare patients) ↓ 1390 to 925; 100,000 pyr LOS 3.1 to 1.9d30,31 |
| ● Ethnicity: 20% and 50% ↑ Hispanics and African Americans, 50% ↓ Asians and whites31; median 30-d readmission rate 21.9% (17%-28.2%), ↓ 1.5% 2010 to 2013, 1-y rate ~67%,26,30-34 |
| ● Mismatch between per capita decline in HHF rates and static or increasing early postdischarge mortality and readmission rates in developed nations.35-40 |
| ● Medication adherence: highest rates in North America (except MRA), Western Europe, and Japan; lowest in Eastern Europe and Asia (excluding Japan) |
| **Patient demographics** |             |
| ● Mean age: 70 to 75y (SD 15y). Social factors affect severity and age at first MACE. |
| ● Sex: Women have better prognosis |
| ● Ethnicity: Very minimal data. Observations suggest earlier presentation and greater severity in some (eg, African American, Hispanics). GWTG-HF intervention study, no racial disparity, and improved in-hospital mortality in African Americans and Hispanics |
| **Clinical characteristics** |             |
| ● Ischemic CHF universal lead cause. Uncontrolled hypertension, valvular heart disease, congenital heart disease in developing nations |
| ● Cardiac comorbidities >40%-70%, eg, IHD, HT, AF |
| ● Noncardiac >33%, eg, CKD, COPD, DM; some underreported, eg, OSA, depression |
| ● Aggravators to CHF treatments, eg, in DM, COPD/chf underreported |
| **Initial clinical presentation** |             |
| ● BP: >50% hypertensive; ~2% <90 mmHg |
| ● Dyspnea—NYHA class IV >34%; class II to III, orthopnea >90% |
| ● Rates >70%; systemic congestion (JVP; peripheral edema) >66% |
| ● CXR >75% pulmonary congestion |
| **Diagnoses** |             |
| ● ↓ Hb—50% mild, 25% moderate; ↓ Na >20; eGFR 10% >90, 20% <30 mL/min/m² |
| ● ECG: baseline 50%, new onset HHF 20%; 33% wide QRS |
| ● Echo: 66% EF<45% |
| **In-hospital and postdischarge outcomes** |             |
| ● IH: mLoS: 4 to 20d; mortality 4% to 30% |
| ● Discharge: readmission 60/90d to 1y—30% and 32%; mortality 60/90d to 1y—5.4% to 14% and 17.4%. |
| ● >50% readmissions noncardiovascular cause |
| **Inpatient management** |             |
| ● Diuretic regimes poorly recorded; geographical variation in inotropes and vasodilators |
| ● <10% undergo procedural intervention, eg, coronary angiography |
| **Morbidity and mortality predictors** |             |
| ● Framingham cohort |
| ● Age, weight, cardiac, and noncardiac comorbidities, systolic blood pressure |
| ● Biochemistry (renal function [BUN and SCr], serum Na, Hb, BNP, Tn), QRS duration, and evidence-based medication utilization |
| ● Admission renal function, systolic BP, elevated B-type NP, and positive Tn suggest particularly high risk for short-term morbidity and mortality |
| ● OPTIMIZE-HF—IH mortality—pneumonia (OR 1.60), worsening renal function (1.48), and ischemia (OR 1.20); postdischarge mortality ischemia (OR 1.52) and worsening renal function (OR 1.46) |
| **Quality improvement initiatives** |             |
| ● Participation in observational registry using benchmark data reports improves outcomes. ADHERE—BB use ↑ 29% (IH) and 30% (discharge); mLoS and IH mortality ↓ 6.3 to 5.5d and 4.5% to 3.2%. |
| ● Participation in interventional registry, eg, OPTIMIZE-HF—BB use ↑ 76% to 86%; ↓ mLoS (P<.05); ↓ trends IH/discharge/other mortality, GWTG-HF and IMPROVE-HF corroborated above study |
| ● Readmission prevention (231): (1) transitional care programs, (2) evidence-based interventions that reduce readmissions (neurohormonal blockade, AICD, CRT, cardiac rehabilitation, and exercise training), (3) emergency room discharge, (4) observation units, (5) outpatient infusion centers, (6) detecting preclinical HF deterioration (eg, technology) |

(Continued)
CHARACTERISTICS REPORTED

KEY FINDINGS

Readmission
- OPTIMIZE-HF—Mean age 73.1 y, 48% men, mean EF 39.0%. About 61.3% of 48,612 patients had ≥1 precipitating factors: pneumonia/respiratory process (15.3%), ischemia (14.7%), and arrhythmia (13.5%) were most frequent.
- Readmissions within 30 d often relate to HF. Causes include (231) the following:
  1. Patient factors: illness severity, social status determinants (race, income, education)
  2. Community factors: hospital resources, community social support institutions
  3. Modifiable factors: regional variations, quality of care (in-patient, discharge instructions, medication dispensing process, ambulatory care access, communication across health providers)

Comorbidities
- Common: HT, CRI, DM, chol., AF, OSA
- Mortality ↑

Abbreviations: 30-dR, 30-day readmission; AF, atrial fibrillation; AICD, automated implantable cardiac defibrillator; BB, β-blocker; BP, blood pressure; BUN, blood urea nitrogen; CHF, congestive heart failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapies; d, days; DM, diabetes mellitus; echo, echocardiography; F, female; Hb, hemoglobin; HHF, hospitalized heart failure; HT, hypertension; IH, in-hospital; HD, ischemic heart disease; JVP, jugular venous pressure; M, male; MACE, major adverse cardiovascular event; mLoS, median length of stay; Na, sodium <135 mEq/L; NP, natriuretic peptide; OR, odds ratio; OSA, obstructive sleep apnea; SCR, serum creatinine; SOA, state of the art; TN, troponin.

This table summarizes selected reviews and registries on HHF, predominately from developed countries worldwide. Data on admission demographics, treatment, and outcomes are presented. Data from developing nations and some racial backgrounds are limited.

Adapted from review and meta-analysis: Previous studies1,10,11,13,17,23,24,41–46 and Appendix 1; stand-alone and trial registries: ADHERE, Acute Decompensated Heart Failure National Registry47–54; ADHERE-AP, Acute Decompensated Heart Failure National Registry International, Asia Pacific55; AHEAD, Acute Heart Failure Database56; ALARM-HF, Acute Heart Failure Global Registry of Standard Treatment56; ARIC, Atherosclerosis Risk in Communities Study58; ATTEND, Acute Decompensated Heart Failure Syndromes59,60; EFICA, Épidémiologie Francaise de l'Insuffisance Cardiaque Aigue61; EHFS II, European Heart Failure Survey II62,63; ESC-HF, European Society of Cardiology, Heart Failure64,65; IN-HF, Italian Registry on Heart Failure66; Ro-AHFS, Romanian Acute Heart Failure Syndromes.67 Intervention: EVEREST, Efficacy of Vasopressin Antagonism in Heart Failure outcome Study With Tolvaptan23,24,68; gWTg-HF, Get With The guidelines—Heart Failure69–74; IMPRoVE-HF, Improve the Use of Evidence-Based Heart Failure Therapies in the outpatient Setting75; OPTIMIZE-HF, Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure.11,76–82

Figure 1. Natural history of heart failure (HF). Diagram demonstrates a 3-phase process once HF is diagnosed. The natural history of HF is chronological progression of left ventricular remodeling, manifesting with symptoms, physical morbidity, and early death. HF readmissions, presenting as acute decompensation, have greatest risks in the transition and palliative phases. The transition forward to more advanced phases is influenced by rate of recovery and normalization of LV function in correlation to the starting point of prior screening (black arrow), early treatment (blue arrow), and through its natural history (read arrow), and the type of cardiomyopathy, energetic defects > toxins > inflammatory causes. The slope of the arrows highlights the trajectory and prolongations toward death. Terminology: (1) Normalization of LV function, defined as an EF >50%; (2) recovery of LV function, defined as an improvement in LF ejection fraction from 5% to 15%; normalization occurs less frequently than recovery of LV function.

Image modified from Fonarow et al.1,4,83

subdomains of a disease management taxonomy could influence readmissions.11,89 A summary of some of these factors include: firstly there are varying complexities in CHF cohort including hospitalization, complexities of comorbidities or risk factors including male sex, advanced age, or disease (eg, low systolic blood pressure), cardiac comorbidity (myocardial ischemia, AF), noncardiac comorbidity burden (CRI, DM, anemia, COPD, hyponatremia), psychosocial well-being (depression, social support, literacy), noncardiac illnesses (respiratory tract infection, falls, and fractures), history and frequency of prior hospitalization, prescription of prognostic medications, patient-related/compliance factors (nonadherence, dietary indiscretion with salt and water with weight gain, and drug and alcohol abuse), iatrogenic factors (eg, use of nonsteroidal anti-inflammatory drugs), and system-related factors (insufficient access to follow-up care and rehabilitation, poor transitions of
Diabetes mellitus

CHF contributes to DM morbidity and mortality through arterial diseases (especially coronary) and independently, ie, “diabetic cardiomyopathies,” an evolving term. Several points are however indisputable: (1) Epidemiology observations—greater chronology and severity of DM with all stages from prediabetes, metabolic syndrome, and established diabetes, risk of CHF ([hazard ratio 1.2 to 1.7] and [12.4 vs 30.9 per 1000 person-years]). 1 in 3 admitted patients shows new-onset impaired glucose tolerance and prevalence in registries range from 25% to 40%; (2) Prognosis—higher rates of morbidity and hospitalizations; (3) Pathophysiology—alterations occur with structural changes in myocardium and vasculature, unfavorable imbalance in myocardial energetics, CRI, and other organ damage. Treatment guidelines highlight the need for excellent DM control but having glaring deficiencies beyond that. Optimal treatment options and dosing are based on limited evidence, often without accounting for potential interactions contributing to suboptimal regimes. Novel pharmacotherapies are also wanting, however, SGLT2 (sodium–glucose cotransporter-2) inhibitors, is one novel agent with potential revolutionary impact on CHF prevention in DM. Strong public policy for education of cardiologists and general practitioners is required to help clinical translation. With existing drugs, vasodilator beta-blockers, with distinct benefits, are not presently factored. Greater evidence is needed for benefits with metformin and sulfonylureas, safe insulin dosing, safety of thiazolidinediones, translation of DPP-4 inhibitors, and GLP-1 receptor antagonist (RAs). Finally, lifestyle modifications are addressed through cardiac rehabilitation or diabetic education and maintained through self-care are underutilized from poor funding; for example the Australian public health fund (Medicare) rebate is for limited duration and restricted to hospital specialist, disadvantaging community specialists and ambulatory patients. This lack of resourcing has not translated as a priority health policy issue.

Chronic renal impairment

The interaction between the failing heart and kidney is always bidirectional. This cardiorenal interaction now labeled “cardiorenal syndrome (CRS)” has been synthesized most comprehensively by Ronco et al. Short-term fluid and electrolyte imbalance, with long-term dysregulation of endocrine, sympathetic, immune (inflammatory) functions of the primary organ (heart or kidney), and secondarily every organ throughout the body contribute to a patient’s clinical presentation. The Acute Decompensated Heart Failure National Registry (ADHERE) database of 175,000 admissions across the Unites States consolidated on the depth of a problem already suspected highlighted that, all grades of CRS contribute to pathology in the other. The risk increasing with baseline severity, where CRI is the single strongest predictor of CHF outcome even beyond LVEF. CRS is also under-detected, and prognostic CHF treatment is often suboptimally prescribed.

Guidelines have been cautious in taking strong positions on pharmacotherapies as advances in diagnostics have been slow. The estimated glomerular filtration rate (eGFR) is the most accurate estimate of CRI but lags by 2 to 7 days in predicting worsening CRI and cannot be used acutely to monitor renal function. Thus, using renin-aldosterone-angiotensin blockers when eGFR is between 20 and 45 mL/m becomes problematic. Novel renal function and injury biomarkers such as cystatin-C and neutrophil gelatinase–associated lipocalin have ongoing translational and cost-efficiency issues. As optimizing conventional CHF therapies at lower eGFRs is difficult, a novel approach to prescribing may be required including agents with extracardiac benefits and targeting systemic factors such as autonomous sympathetic overactivity, nitric oxide deficiency, and endothelial dysfunction. For acute heart failure, vasodilators (nesiritide; currently only selected patients), vasopressin antagonist (volume overload and resistant hyponatremia) and novel agents (serelaxin and ularitide) offer alternative permutations for combination therapies in nephroprotection with CHF. We anticipate stonger positions in newer guidelines.

Chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease is present in a third of CHF cases, has an equal sex distribution despite a greater rate of smoking in men (suggesting greater susceptibility in women), and predicts mortality. Chronic obstructive pulmonary disease poses some unique challenges. First, it can be underdiagnosed due to underutilization of pulmonary function tests. Second, diagnostic challenges as the symptom of dyspnea is similar for both conditions. As pulmonary function tests are unreliable in acute settings, novel biomarkers such as B-type natriuretic peptide have been used, but more work is needed as up to 40% of respiratory distress are incorrectly admitted between cardiac and general medical units. Third, therapeutic issues such as underprescription of beta-blockers in CHF while use of steroids and beta-adrenergic agonist can enhance fluid retention and increase heart rates. The optimal cardioselective beta-blockers is another area
Table 2. Clinical characteristics of young versus elderly with acute heart failure (AHF).

|                        | YOUNG                                                                 | ELDERLY                                                                 |
|------------------------|----------------------------------------------------------------------|------------------------------------------------------------------------|
| Clinical profile       | Men, obese, diabetic, coronary artery disease, less non-CV comorbidities | Women, hypertensive, nonobese, nonobese, atrial fibrillation, non-CV comorbidities (stroke, peripheral vascular disease, anemia, frailty) |
| Clinical presentation  | Cardiac-type HF, Lower SBP, higher peripheral edema                   | Vascular-type HF, Rules, high SBP, increased JVP, low                  |
| HF history             | Less rates                                                           | Arterial oxygen saturation, infection                                  |
| Laboratory findings    | Acutely decompensated chronic HF                                      | New-onset HF                                                           |
|                        | Prior HF hospitalization                                              | No recent HF hospitalization                                           |
| Echocardiography       | Higher eGFR, lower levels of NPs                                      | Lower eGFR, higher SUN, higher levels of NPs, lower Hb                 |
| Treatment              | Reduced LV systolic function                                          | Preserved LV systolic function, diastolic dysfunction, LA dilatation  |
| Highest risk           | Higher diuretic doses, more inotropes                                 | Lower diuretic doses, less inotropes                                   |
|                        | More BB, ACEI/ARBs/MRAs                                               | Less BB, ACEI/ARBs/MRAs                                                |

Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; BB, β-blocker; CS, cardiogenic shock; CV, cardiovascular; eGFR, estimated glomerular filtration rate; Hb, hemoglobin; JVP, jugular venous pressure; LA, left atrium; LV, left ventricle; MRA, mineralocorticoid receptor antagonists; NP, natriuretic peptide; NYHA, New York Heart Association; SBP, systolic blood pressure; SUN, serum urea nitrogen.

Table data from Brouwers et al.22

Heart Failure in the Elderly

Defining elderly with a cutoff age of 70 to 80 years, registries have shown that >50% of acute HF admission (elderly - mean age 75 years or octogenarian ≥80 years) range between 21% and 38%. Studies also demonstrate age differences in demography, clinical profiles and outcomes, comorbidities, and prognostic factors. Elderly presentations are ≥60% women, where 45% are new-acute HF, more likely associated with hypertension and AF, and less likely obese and diabetic. Respiratory distress is more common than peripheral edema, and atypical symptoms of sepsis, fever, confusion, fatigue, and loss of appetite are associated and added to the diagnostic difficulties (Table 2).13,22,23,56,60,68–92

Registries comparing prognostic medications with age such as IN-CHF (>70 years), OPTIMIZE-HF (>75 years), and EuroHeart Failure Survey II (EHFS II; >80 years) support significantly lower prescribing rates.13,23,68,73,74 Physiological differences with HFPeF, signs of organ impairment (lower eGFR), and perhaps uncertainty as to diagnosis and functional status influence practices. In EHFS II, and confirmed in other registries, various grades of frailty among the elderly were demonstrated by decline of independent function, self-care, and QOL with increased dependency for supported care. Data show >70% HF patients >80 years of age may be vulnerable, and this is assessable by “frailty scores.” As relatives and
support services assume more care, communication pathways can become more complex even resulting in prescribing that is suboptimal or too complex.13,22,102 Gaps in organized clinical pathways undoubtedly contribute to high readmissions.

Cognitive decline could point to a range of pathologies. There is, however, no direct evidence that HF medication contributes to dementia. Mood disorder or depression is an important consideration for pseudodementia. Decompensated HF could manifest as acute delirium with prolonged hospital stay and higher mortality. Palliative and end-of-life care are usually provided after consultation with families, specialist, general practitioners, and allied health teams. In the Australian health system, providing this service with predictable intensity and duration in hospices are not a huge contributor to readmissions. In the absence of structured care, the need for regular communication and monitoring from patients or their supports, significantly contributes to high readmission rates within 3 to 6 months from discharge between 27% and 47%, where 50% relates to medication, disability, or an associated comorbid condition.22,70,71

Specific therapeutic considerations

Three major uncertainties are noted. First, the altered physiology with aging; altered pharmacodynamics, with increasing hepatic and renal impairment in the main excretory organs for drugs; and pharmacokinetics with reduced total body water content, body mass, and fat tissue. The resulting lower volume of distribution with either low or high plasma concentrations of lipophilic or hydrophilic drugs alters drug effects. Second, two thirds of elderly have >2 noncardiac comorbidities and 25% have 6 or more noncardiac comorbidities. When associated with cognitive decline and polypharmacy (average of 10 medications) influences compliance and lowers safety for adverse events. Third, available social supports and ability to achieve high levels of self-efficacy can influence optimal prescribing.70

Proven prognostic therapies include RAAS inhibitors and β-blockers. Digoxin and diuretics are mainstay for symptoms. All drug classes require close monitoring of weight, electrolytes, renal function and cardiac haemodynamics. Serum digoxin levels >0.9 nmol/L have cognitive and mortality consequences. Angiotensin-converting enzyme inhibitor long-term benefits above 75 years decline, and angiotensin receptor blockers could be more beneficial.72,73 Eplerenone could have greater tolerability as 10% of men have gynecomastia as testosterone declines with age. β-blocker data are limited; however, tolerability appears lower than younger HF patients (84% vs 76%). In an older HF population, nebivolol improved readmissions and mortality for both systolic and diastolic HF.22,70,74

Finally, with devices, morbidity and mortality are higher in patients >80 years without clear outcome benefits.58

Guideline gaps

The differences seen in the elderly excluded from RCT are co-morbidities and physiological changes of aging including an inherent increase by age alone. It thus remains unclear how much prognosis is genuinely extended or by a lead-time bias effect. Thus, factoring guidelines for octogenarians remains difficult. However, some principles must guide therapy:

1. Improved representation in trials, clinical trials, starting with post-marketing trials.
2. Delivering all proven therapies in conjunction with geriatric teams, achieving maximal tolerable or safe doses;
3. Regular monitoring of treatments with comparable use of diagnostics;
4. Minimizing polypharmacy in all other areas, by prioritizing prognostic and QOL improving agents;
5. Protocols when admitted to general medical units;
6. Protocols for early and appropriate palliative care referrals for severely deconditioned.

Closing the Gaps

The past 2 millennia have seen the fastest advancements in public health and innovations from assessment to therapies. Universal life expectancy has increased globally when compared with any historical baseline. The evidence generating process and implementation strategies have been the biggest contributors. However, as populations develop diseases later in life or survive for longer, the variables for each patient gradually exceed the boundaries or predefined internal validity parameters of trials. We are thus starting to see plateaus in the health of subgroups, such that health budgets escalate, but cost-efficiency (or return of investment) is not readily noticeable. There is a new phase of medical practice on the horizon, one that will incorporate a greater flexibility in prescribing and management and draw in technological advances. The failure to reproduce trial-level evidence at the population level is the greatest proponent for this argument. The concept of phase 4 or postmarketing studies is well defined but not translated into clinical practice. Moving forward, several avenues to consider are discussed (Figure 2).

Identification and classification of HF patients

As most of the proven evidence is derived from younger patients, health clusters must be able to develop systems that expands the efficacy of findings to all CHF patients. A surge of resources could be used at this point. While a similar prognostic target should not be denied, resources must be used to identify the support networks and readmission risks. Such scoring systems are not well developed (Table 1).13
Databases—standardizing and prioritizing implementable key performance indicators

The ability to assess real-time performance of CHF programs is vital. The AHA has published the important domains and dimensions of care, systematically going through each of this and more importantly finding a way to determine the key performance indicators, where intervention policy should be delivered will make a great impact on the measured outcome. Such information will inform risk scoring or act as a feeder for a phase 4 trials with different variables from the evidenced RCT.

Evidence generation and outcome measures—RCT or other

Defining roles. Health practitioners are defined and remunerated for clinical services, researchers for productivity in generating new knowledge, and a percentage of clinical researchers manage to function in both camps. However, it has never been entirely clear what roles health practitioners have in auditing their clinical work particularly in relation to cost-efficiency. Larger tertiary hospitals and entire systems like the British National Health System have this as a prerequisite. The responsibility to determine whether public-funded therapeutics is delivering benefits must be part of more than less systems, preferentially over-sighted by accrediting bodies. This will ensure when auditing systems are not in place, collaborations with institutes can be facilitated.

Gaps in guidelines. Gaps in guidelines can only be addressed by generating translatable evidence. This requires resourcing, infrastructure, personnel, and wide support:

1. Investigator-sponsored noninferiority studies: Posttranslational (phase 4) research is underutilized. Clinicians in practice will notice that with comorbidities and elderly, the external validity of RCT findings is not clearly demonstrated in real-world practice. While the scientific community does not argue against the accepted physiological basis for therapeutic benefits, the properties of one individual drug may come into question when a variant clinical scenario presents itself. Some examples here are diuretics and some renin-angiotensin blockers (e.g. lisinopril, losartan) and black race and HF-class and vasodilatory β-blockers. Health systems must also achieve consensus on what constitutes translatable evidence (i.e. allows local clinicians to vary practice) and what methods to use to allow for broader question and experiments (e.g. prospective audits with nested interventions or quasi-experimental studies). A noninferiority outcome for the primary and comorbid condition could be acceptable.
2. Novel research and institutional partnership: Strengthening existing institutes by partnering could allow for bidirectional benefits. Most research institutes will benefit from having access to patients, and most clinical centers will benefit from the research or trial effect. Research governance requires robust support and secure infrastructure. The added personnel also imparts a culture of learning and accountability.

Improving evidence translation and cost-efficiency

1. Rapid translation of novel therapies: Complex patients could benefit from regular structured complex case management meetings. Incorporating relevant primary care providers is crucial; remuneration is not presently factored. At these sessions, all available proven therapies relevant to all comorbidities are discussed. Several examples are SGLT-1 inhibitors, bariatric surgery, and atrial fibrillation ablations, all conditions that persist for the patient’s life. The ability to significantly change the trajectory of a comorbid condition that alters CHF prognosis and influences prognosis must always be discussed robustly.

2. Engaging community and policymakers: It has never been clear what role tertiary institutions plays in prevention, yet this is often the first front to be looked at when outcomes such as readmissions are questioned. Part of this process involves delineating the community and primary care services within its primary catchment and offers regular health updates and promotes regional evidence development. Patient days where specialist units are open to the public could be factored. Strengthening understanding with governmental bodies and research governance bodies that increase the weighting of locally generated evidence and prerequisites for auditing of costly new treatments into health clusters are also considerations.

Conclusions

Readmissions in CHF are a surrogate outcome for delivery of optimal care. Although inroads have been made in improving these statistics, the growing and aging population predicts an increase in resource utilization, economic costs, and wider discrepancies in outcomes with multiple comorbidities and in the elderly. Registries have identified markers of readmission and prognostic risk; however, such information is unlikely to translate to any meaningful bedside use in the foreseeable future. Comorbidities and the elderly often have less robust evidence, as they are excluded from studies in run-in-period or outright. They may require special considerations in diagnostics, choices of therapies including dosing, and other pharmacologic considerations. As the number of questions to be asked is vast, regular quality assurance audits with prospective databases are essential. In the real world, heterogeneity in demographics and lack of relevant models of services offer few choices for a diverse problem. Several process-of-care publications on chronic disease management programs and performance markers have provided a unique opportunity to standardize CHF programs. Although the randomized clinical trial would create an artificial lens to view outcomes for CHF in the real world, it provides a solid template to conduct posttranslational or phase 4 research. The completion of cost-efficiency exercise requires a further bridge for a gap in what is considered acceptable translation research that should be funded by local authorities. Service-based research to reduce readmissions should thus primarily be focused on cost-efficiency and generating translatable research within an agreed standardized framework, for more universal acceptance. Treatments that directly improve the disease trajectory should also be explored with broad stakeholders, where again translation is the priority. Clinical outcomes including improved readmissions are the likely beneficiaries.

Author Contributions

PI conceived and designed the experiments, analyzed the data and wrote the first draft of the manuscript. PI, DL, CN, AD, THM, DLH contributed to the writing of the manuscript. PI, DL, CN, AD, THM, DLH agree with manuscript results and conclusions. PI, DL, CN, AD, THM, DLH jointly developed the structure and arguments for the paper. PI, DL, CN, AD, THM, DLH made critical revisions and approved final version. All authors reviewed and approved of the final manuscript.

REFERENCES

1. Desai AS, Stevenson LW. Rehospitalization for heart failure: predict or prevent? Circulation. 2012;126:501–506.
2. Clinton G, Johnson G, Franci G, Cobb F, Cohn JN. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87:VI17–VI23.
3. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics—2008 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation. 2008;117:e25–e146.
4. Chaudhry SP, Stewart GC. Advanced heart failure: prevalence, natural history, and prognosis. Heart Fail Clin. 2016;12:321–333.
5. Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016;13:368–378.
6. Blecker S, Paul M, Taksler G, Ogedegbe G, Katz S. Heart failure associated hospitalizations in the United States. J Am Coll Cardiol. 2013;61:1259–1267.
7. Chun S, Tu JV, Wijeysundera HC, et al. Lifetime analysis of hospitalizations and survival of patients newly admitted with heart failure. Circ Heart Fail. 2012;5:414–421.
8. Cubbon RM, Gale CP, Kearney LC, et al. Changing characteristics and mode of death associated with chronic heart failure caused by left ventricular systolic dysfunction: a study across therapeutic eras. Circulation. 2011;4:396–403.
9. Joynt KE, Jha AK. Who has higher readmission rates for heart failure, and why? Implications for efforts to improve care using financial incentives. Circ Cardiovasc Qual Outcomes. 2011;4:53–59.
10. Ross JS, Chen J, Lin Z, et al. Recent national trends in readmission rates after heart failure hospitalization. Circulation. 2010;3:97–103.
11. Krumholz HM, Merrill AR, Schone EM, et al. Patterns of hospital performance in acute myocardial infarction and heart failure 30-day mortality and readmission. Circ Cardiovasc Qual Outcomes. 2009;2:407–413.
12. Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med. 1994;331:1564–1575.
13. Soundararaj D, Singh V, Sarjia V, Thakur RK. Containing the cost of heart failure management: a focus on reducing readmissions. Heart Fail Clin. 2017;13:21–28.
14. Iyngkaran P. Editorial: optimizing chronic heart failure care beyond randomised controlled trials – what are the problem areas and potential solutions? Curr Cardiol Rev. 2016;12(3):164–165.
15. Zannad F, Agninier N and Alla F. Heart failure burden and therapy. *European Heart Journal*. 2009;31:1–9.

16. Braunwald E. The war against heart failure: the Lancet lecture. *Lancet*. 2015;385:812–822.

17. Konstam MA. Seeking therapeutic precision in heart failure: is ejection fraction really the way do we approach the CHARM of heart failure with mid-range ejection fraction. *Eur J Heart Fail*. 2018; 20:1240–1242. doi:10.1002/ejhf.1205.

18. Fonarow GC, Abraham WT, Albert NM, et al. Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF). *Arch Intern Med*. 2007;167:1493–1502.

19. Iyngkaran P, Liew D, McDonald P, et al. Phase 4 studies in heart failure—what is done and what is needed? *Curr Cardiol Rev*. 2016;12:216–230.

20. Ferreira JP, Gireder N, Rossignol P, Zannad F. Geographic differences in heart failure trials. *Eur J Heart Fail*. 2015;17:893–905.

21. Iyngkaran P, Majoni W, Casu A, et al. Northern territory perspectives on heart failure with comorbidities—understanding trial validity and exploring collaborative opportunities to broaden the evidence base. *Heart Lung Circ*. 2015;24:536–543.

22. Kattanaso S, Bistola V, Parisis JY. Acute heart failure syndromes in the elderly: the European perspective. *Heart Lung Circ*. 2015;13:673–645.

23. Dharmanar K, Rich MW. Epidemiology, pathophysiology, and prognosis of heart failure in older adults. *Heart Fail Clin*. 2017;13:417–426.

24. Gheorghiade M, Vayghanathan M, Fonarow G, Bonow RO. Rehospitalization for heart failure: a randomized, controlled perspective. *Am J Cardiol*. 2013;113:391–403.

25. Roger VL. Epidemiology of heart failure. *Circ Rev*. 2013;113:646–659.

26. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. *Nat Rev Cardiol*. 2011;8:30–41.

27. Setoguchi S, Stevenson LW, Schnerrseins S. Repeated hospitalizations predict mortality and quality of life in the community population with heart failure. *Am J Med*. 2007;114:260–266.

28. Gudwar-Sridhar FH, et al. A systematic review and meta-analysis of studies comparing readmission rates and mortality rates in patients with heart failure. *Arch Intern Med*. 2004;164:2315–2320.

29. Centers for Medicare and Medicaid Services. Chronic Conditions Among Medicare Beneficiaries (Chartbook). Baltimore, MD: Centers for Medicare and Medicaid Services; 2012.

30. Hummel SL, Pauli NP, Krusholz HM, et al. Thirty-day outcomes in Medicare patients with heart failure at heart transplant centers. *Circ Heart Fail*. 2015;8:324–331.

31. Ahmad T, Pencina MJ, Schulte PJ, et al. Clinical implications of chronic heart failure phenotypes defined by cluster analysis. *J Am Coll Cardiol*. 2014;64:1765–1774.

32. Mente RJ, Kelly JP, von Loeder TG, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. *J Am Coll Cardiol*. 2014;64:2281–2293.

33. Ernande L, Derumeaux G. Diabetic cardiomyopathy: myth or reality? *Arch Cardiovasc Dis*. 2012;105:218–225.

34. Lebheke M, Max N. Diabetes mellitus and heart failure. *Am J Cardiol*. 2017;120:S37–S47.

35. Iyngkaran P, Harris M, Ilton M, et al. Implementing guideline based heart failure care in the northern territory: challenges and solutions. *Heart Lung Circ*. 2014;23:391–406.

36. Iyngkaran P, Toukhari SR, Thomas MC, Jelinek MV, Hare DL, Horowitz JD. A review of the external validity of clinical trials with beta-blockers in heart failue. *Clin Cardiol*. 2011;34:119–127.

37. Smith BM, Prinsen MR, Hoffman EA, et al. Impaired left ventricular filling in COPD and emphysema: is it the heart or the lungs? the multi-ethnic study of atherosclerosis COPD study. *Circ*. 2013;144:1131–1511.

38. Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a systematic review of randomized controlled trials. *J Am Coll Cardiol*. 2010;55:1780–1787.

39. Mente RJ, Fuzat M, Kraft M, Lindenfeld J, O’Connor CM. Bronchodilators in heart failure patients with COPD: is it time for a clinical trial? *J Card Fail*. 2012;18:413–422.

40. Sin DD, Fitzgerald F, Parker JD, et al. Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure. *Am J Respir Crit Care Med*. 1999;160:1101–1106.

41. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. *Circulation*. 2016;133:e38–e360.

42. Metta M, Mentz RJ, Chiswell K, et al. Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial. *Eur J Heart Fail*. 2015;17:109–118.

43. Mogensen UM, Erboll M, Andersen M, et al. Clinical characteristics and major comorbidities in heart failure patients more than 85 years of age compared with younger age groups. *Eur J Heart Fail*. 2015;17:1126–1131.

44. Murad K, Goff D, Morgan T, et al. Burden of comorbidities and functional and cognitive impairments in elderly patients at the initial diagnosis of heart failure and their impact on total mortality: the cardiovascular health study. *J Am Coll Cardiol*. 2015;65:542–550.

45. Metta M, Conter G, El-Khourazty J, et al. Acute heart failure in the elderly: differences in clinical characteristics, outcomes, and prognostic factors in the VERITAS study. *J Card Fail*. 2015;21:179–188.

46. Ramani GV, McCloseky C, Ramanathan RC, et al. Safety and efficacy of bariatric surgery in morbidly obese patients with severe systolic heart failure. *Circ Cardiovasc Qual Outcomes*. 2008;1:516–520.

47. Paulino A, Damy T, Margarit L, et al. Prevalence of sleep-disordered breathing in a 316–patient French cohort of stable congestive heart failure. *Arch Cardiovasc Dis*. 2009;102:169–175.

48. Kassai T, Bradley TD. Obstructive sleep apnea and heart failure: pathophysiology and therapeutic implications. *J Am Coll Cardiol*. 2011;57:119–127.

49. Bradley TD, Logan AG, Kimoff RJ, et al. CANPAP investigators. Continuous positive airway pressure for central sleep apnea and heart failure. *N Engl J Med*. 2005;353:205–2033.

50. Lavie CJ, McAuley PA, Church TS, et al. Obesity and cardiovascular diseases: implications for fitness, fatness, and severity in the obesity paradox. *J Am Coll Cardiol*. 2014;63:1345–1354.

51. Poirier P, Cornier MA, Mazzone T, et al. Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association. *Circulation*. 2012;126:1687–1701.

52. Mandiwanda T, Khalid U, Deswal A. Obesity and cardiovascular disease: a risk factor or a risk marker? *Curr Atheroscler Rep*. 2016;18:21.

53. Iacovelli M, Antonacci C, V. Heart failure in elderly: progression in clinical evaluation and therapeutic approach. *J Geriatr Cardiol*. 2013;10:163–177.

54. Rich MW. Management of heart failure in the elderly. *Heart Fail Rev*. 2002;7:89–97.

55. Lemay G, Azad N. Management of chronic heart failure in the older population. *J Geriatr Cardiol*. 2014;11:329–337.

56. Wong CY, Chaudhry SI, Desai MM, et al. Trends in comorbidity, disability, and polypharmacy in heart failure. *Am J Med*. 2015;124:436–443.

57. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure and left-ventricular dysfunction: a systematic overview of data from individual patients. *Lancet*. 2000;355:1575–1581.
73. Pfeffer MA, Swedberg K, Granger CB, et al. Effect of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM–overall program. Lancet. 2003;362:759–766.

74. Rich MW. Pharmacotherapy of heart failure in the elderly: adverse events. Heart Fail Rev. 2012;17:589–595.

75. Komajda M, Hanout O, Hochadel M, et al. Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. Eur Heart J. 2009;30:478–486.

76. Stein GY, Kremer A, Shochat T, et al. The diversity of heart failure in a hospitalized population: the role of age. J Card Fail. 2012;18:645–653.

77. Herrera-Porto P, Martin-Sanchez FJ, Fernandez-Fernandez M, et al. Differential clinical characteristics and outcome predictors of acute heart failure in elderly patients. Int J Cardiol. 2012;155:81–86.

78. Tinetti ME, McAvay GJ, Chang SS, et al. Contribution of multiple chronic conditions to universal health outcomes. J Am Geriatr Soc. 2011;59:1686–1691.

79. Chaudhry SE, Wang Y, Gill TM, Krumholz HM. Geriatric conditions and subsequent mortality in older patients with heart failure. J Am Coll Cardiol. 2010;55:309–316.

80. Pulignano G, Del Sindaco D, Tavazzi L, et al. Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a nationwide cardiology database (IN-CHF registry). Am Heart J. 2002;144:45–55.

81. Fonarow GC, Abraham WT, Albert NM, et al. Factors identified as precipitating hospital admission for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Am J Cardiol. 2009;104:107–115.

82. Majbour H, Riusinara D, Souliere V, et al. Long-term survival in patients older than 80 years hospitalised for heart failure. A 5-year prospective study. Eur J Heart Fail. 2008;10:78–84.

83. Burchfeld JS, Xie M, Hill JA. Pathological ventricular remodelling: mechanisms part I. Circulation. 2012;135:388–400.

84. Rush CJ, Campbell RT, Bhund PS, et al. Falling cardiovascular mortality in heart failure with reduced ejection fraction and implications for clinical trials. JACC Heart Fail. 2015;3:603–614.

85. Grover MM, Mann DL. Epidemiology and natural history of recovery of left ventricular function in recent onset dilated cardiomyopathies. Curr Heart Fail Rep. 2013;10:321–330.

86. Desai AS. The three-phase terrain of heart failure readmissions. Circ Res. 2012;5:397–399.

87. Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of hospitalizations for heart failure: lessons learned from hospital heart failure registries. J Am Coll Cardiol. 2014;63:1123–1133.

88. Iyngkaran P, Tinsley J, Smith D, et al. Northern territory heart failure initiative—a clinical audit (NTHFI-CA)—a prospective database on the quality of care for elderly patients. J Card Fail. 2012;18:645–653.

89. Givertz MM, Mann DL. Epidemiology and natural history of recovery of left ventricular function in recent onset dilated cardiomyopathies. Circulation. 2006;114:1432–1445.

90. Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of heart failure. JAMA. 2012;308:623–632.

91. Krumholz HM, Parent EM, Tu N, et al. Readmission after hospitalization for heart failure: a systematic review and analysis. JAMA. 2016;315:469–481.

92. Ferrero P, Iacovoni A, Di Elia E, Vaduganathan M, Gavazzi A, Senni M. Prognostic sign in patients with acute heart failure? the role of congestion and its interaction with renal function. Arch Intern Med. 2012;172:365–372.

93. Echouffo-Tcheugui JB, Greene SJ, Papadimitriou L, et al. Population risk prediction models for incident heart failure: a systematic review. Eur Heart J. 2016;37:1371–1386.

94. Yang H, Negishi K, Otahal P, et al. Clinical prediction of incident heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. Circulation. 2017;136:1–75.

95. Iyngkaran P, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. Circulation. 2016;134:e282–e293.

96. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2013;128:e240–e327.

97. Konikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37:2125–2200.

98. Arnett DK, Goodman RA, Halperin JL, et al. AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and US department of health and human services. Circulation. 2014;130:1667–1677.

99. Iorio A, Pozzi A, Senni M. Addressing the heterogeneity of heart failure in future randomized trials. Curr Heart Fail Rep. 2017;14:197–202.

100. Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003;42:1226–1233.

101. Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012;59:998–1005.

102. Luscher TF. Heart failure and comorbidities: renal failure, diabetes, atrial fibrillation, and inflammation. Eur Heart J. 2015;36:1415–1417.

103. Shaffer JA, Maurer MS. Multiple chronic conditions and heart failure. JACC Heart Fail. 2015;3:551–553.

104. Bahrami H, Kronmal R, Blument DA, et al. Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis. Arch Intern Med. 2008;168:2138–2145.

105. Fonarow GC, Abraham WT, Albert NM, et al. Factors identified as precipitating hospital admission for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med. 2008;168:847–854.

106. Joynt KE, Jha AK. Thirty-day readmissions—truth and consequences. N Engl J Med. 2012;366:1366–1369.

107. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in Medicare fee-for-service program. N Engl J Med. 2009;360:1418–1428.

108. Saito M, Negishi K, Marwick TH. Meta-analysis of risks for short-term readmission in patients with heart failure. Am J Cardiol. 2016;117:626–632.

109. Zaya M, Phan A, Schwarz ER. Predictors of re-hospitalization in patients with chronic heart failure. World J Cardiol. 2012;4:23–30.

110. Fonarow GC, Abraham WT, Albert NM, et al. Factors identified as precipitating hospital admission for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med. 2008;168:847–854.

111. Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012;59:998–1005.

112. Chuang S, Burkhoff D, Gheorghiade M, Reid KJ, et al. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circ Cardiovasc Qual Outcomes. 2012;5:397–401.

113. Epstein AM, Jha AK, Orav EJ. The relationship between hospital admission rates and rehospitalizations. N Engl J Med. 2011;365:2287–2295.

114. Van Walraven C, Bennett C, Jennings A, Austin PC, Forster AJ. Proportion of hospital readmissions deemed avoidable: a systematic review. CMAJ. 2011;183:E91–E92.

115. Setoguchi S, Stevenson LW. Hospitalizations in patients with heart failure: who and why. J Am Coll Cardiol. 2009;54:1703–1705.

116. Kerkhof PLM, Peace RA, Macfarlane PW. Sex- and age-related reference values in cardiology, with annotations and guidelines for interpretation. Exp Med Biol. 2018;1065:677–706. doi:10.1007/978-3-319-77932-4_41.

117. Perrone-Filardi P, Paolillo S, Costanzo P, Savaresi G, Trimarco B, Bonow RO. The role of metabolic syndrome in heart failure. Eur Heart J. 2015;36:2630–2634.
23. Zarrinkoub R, Schneider H, Devajaran P, Anavekar N, Krum H, Ronco C. Cardio-renal syndrome: new perspective in diagnostics. *Semin Nephrol*. 2012;32:3–17.

24. Meier P, Wettermark B, Wändell P, et al. The epidemiology of heart failure in Framingham Heart Study subjects. *Circulation*. 1993;88:107–115.

25. Ho K, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. *Circulation*. 1971;85:1441–1446.

26. Levy D, Kannel WJ, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. *N Engl J Med*. 2002;347:1397–1402.

27. MacIntyre K, Acker WR, Henneke P, et al. The epidemiology of congestive heart failure: the Framingham Heart Study perspective. * Glob Heart*. 2013;8:77–82.

28. Brouwers FP, de Boer RA, van der Harst P, et al. Incidence and epidemiology of heart failure with preserved versus reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. *Eur Heart J*. 2013;34:1424–1431.

29. Pillai HS, Ganapathi S. Heart failure in South Asia. *Curr Cardiol Rev*. 2015;11:54–63.

30. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

31. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

32. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

33. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

34. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

35. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

36. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

37. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

38. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

39. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

40. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

41. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

42. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

43. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

44. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

45. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

46. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

47. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

48. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

49. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

50. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

51. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

52. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

53. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

54. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

55. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

56. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

57. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

58. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

59. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

60. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

61. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

62. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

63. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

64. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

65. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

66. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

67. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

68. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

69. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.

70. Carson PE, Chatterjee K, Faxon DP, et al. Association of outpatient heart failure process-of-care measures and mortality. *J Am Coll Cardiol*. 2016;68:1051–1060.
55. Egwim C, Dixon B, Ambrosy AP, Mente RJ. Global variations in patient popu-
lations and outcomes in heart failure clinical trials. *Circ Heart Fail Rep.* 2017;14:30–39.

56. Frigerio M, Mazzali C, Pagani AM, et al. Trends in heart failure hospitaliza-
tions, patient characteristics, in-hospital and 1-year mortality: a population study, from 2000 to 2012 in Lombardy. *Int J Cardiol.* 2017;236:310–314.

57. Heywood JT, Fonarow GC, Costanzo MR, et al. High prevalence of renal dys-
function and its impact on outcome in 118,465 patients hospitalized with acute
decompensated heart failure: a report from the ADHERE database. *J Card Fail.* 2007;13:422–430.

58. Fonarow GC, Heywood JT, Heidenreich PA, et al. Hospitalizations and outcomes in heart failure hospital-
pizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Regis-
try (ADHERE). *Am J Heart.* 2007;153:1021–1028.

59. Heywood JT. The cardiorenal syndrome: lessons from the ADHERE database and a treat-
teum options. *Am Heart J.* 2005;149:

60. Adams KF, Fonarow GC, Emerman CL, et al.; ADHERE Scientific Advisory
Committee and Investigators. Characteristics and outcomes of patients
hospitalized for heart failure in the United States: rationale, design, and
preliminary observations from the first 100,000 cases in the Acute Decon-
pensated Heart Failure National Registry (ADHERE). *Am J Heart.* 2005;149:

61. Adams KF, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients
hospitalized for heart failure in the United States: rationale, design,
and preliminary observations from the first 100,000 cases in the Acute Decon-
pensated Heart Failure National Registry (ADHERE). *Am J Heart.* 2005;149:

62. Abraham WT, Adams KF, Fonarow GC, et al. In-hospital mortality in patients
with acute decompensated heart failure requiring intravenous vasoactive medica-
tions: an analysis from the Acute Decompensated Heart Failure National Regi-
try (ADHERE). *J Am Coll Cardiol.* 2005;46:57–64.

63. Abraham WT, Adams KF, Fonarow GC, et al. Admission, discharge, or change in
B-type natriuretic peptide and long-term outcomes: data from Organized Pro-
gram to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Fail-
ure (OPTIMIZE-HF) linked to Medicare claims. *Circulation.* 2011;124:638–636.

64. Fonarow GC, Abraham WT, Albert NM, et al. Day of admission and clinical
outcomes for patients hospitalized for heart failure: findings from the Organized
Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Fail-
ure (OPTIMIZE-HF). *Circ Heart Fail.* 2008;1:50–57.

65. Fonarow GC, Abraham WT, Albert NM, et al. Factors identified as precipit-
ating hospital admissions for heart failure and clinical outcomes: findings from
OPTIMIZE-HF. *Arch Intern Med.* 2008;168:847–854.

66. Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and
outcomes of patients with preserved systolic function hospitalized for heart fail-
ure: a report from the OPTIMIZE-HF Registry. *J Am Coll of Cardiol.*

67. O’Connor CM, Abraham WT, Albert NM, et al. Predictors of mortality after
discharge in patients hospitalized with heart failure: an analysis from the Orga-
nized Program to Initiate Lifesaving Treatment in Hospitalized Patients with
Heart Failure (OPTIMIZE-HF). *Am J Heart.* 2008;156:662–673.

68. Fonarow GC, Abraham WT, Albert NM, et al. Factors identified as precipit-
ating hospital admissions for heart failure and clinical outcomes: findings from
OPTIMIZE-HF. *Arch Intern Med.* 2008;168:847–854.

69. Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with
acute heart failure. *Am J Card Fail.* 2006;12:217–226.

70. Fonarow GC, Albert NM, Curtis AB, et al. Improving evidence-based care for
heart failure in outpatient cardiology practices: primary results of the Registry to
Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). *Circulation.* 2010;122:585–596.

71. Heidenreich PA, Hernandes AF, Yancy CW, Ling, L, Peterson ED, Fonarow
GC. Get with the guidelines program participation, process of care, and outcome for Medicare patients hospitalized with heart failure. *Circ Cardiovasc Qual Out-
comes.* 2012;5:37–43.

72. Kociol RD, Peterson ED, Hammill BG, et al. National survey of hospital strate-
ges to reduce heart failure readmissions: findings from the Get With the Guider-
lines–Heart Failure registry. *Circ Heart Fail.* 2012;5:680–687.

73. Expen ZJ, Fonarow GC, Dai D, et al. Comparison of comprehensive measure meth-
odologies for rewarding quality of care: an analysis from the American Heart
Association’s Get With The Guidelines program. *Circ Cardiovasc Qual Out-
comes.* 2011;4:610–618.

74. Fernandez AF, Fonarow GC, Liang L, Heidenreich PA, Yancy C, Peterson ED. The
need for multiple measures of hospital quality: results from the Get With the
Guidelines-Heart Failure Registry of the American Heart Association. *Circula-
tion.* 2011;124:715–719.

75. Danay SM, Gheorghiade M, Reid KF, et al. Critical elements of clinical follow-
up after hospital discharge for heart failure: insights from the EVEREST trial.
*J Heart Fail.* 2010;12:367–374.

76. O’Connor CM, Miller AB, Blair JE, et al. Causes of death and rehospitalization
in patients hospitalized with worsening heart failure and reduced left ventricular
ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Fail-
ure Outcome Study with Tolvaptan (EVEREST) program. *Am J Heart.* 2010;159:841–849.

77. Gheorghiade M, Pang PS, Ambrosy AP, et al. A comprehensive, longitudinal
description of the in-hospital and post-discharge clinical, laboratory, and neurohor-
monal course of patients with heart failure who die or are re-hospitalized within 90
days: analysis from the EVEREST trial. *Heart Fail Rev.* 2012;17:485–509.

78. Steinberg BA, Zhao X, Heidenreich PA, et al. Trends in patients hospitalized
with heart failure and preserved left ventricular ejection fraction: prevalence,
therapies, and outcomes. *Circulation.* 2012;126:65–72.
